share_log

Are Yunnan Baiyao Group Co.,Ltd's (SZSE:000538) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Are Yunnan Baiyao Group Co.,Ltd's (SZSE:000538) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

雲南白藥集團股份有限公司(SZSE:000538)的複合財務是否導致股市表現低迷?
Simply Wall St ·  07/18 18:23

It is hard to get excited after looking at Yunnan Baiyao GroupLtd's (SZSE:000538) recent performance, when its stock has declined 7.6% over the past three months. It is possible that the markets have ignored the company's differing financials and decided to lean-in to the negative sentiment. Fundamentals usually dictate market outcomes so it makes sense to study the company's financials. In this article, we decided to focus on Yunnan Baiyao GroupLtd's ROE.

雲南白藥集團有限公司(SZSE:000538)股價在過去三個月下跌了7.6%,這讓人很難爲其表現感到興奮。市場可能忽略了該公司具體的財務情況而傾向於消極情緒。基本面通常決定市場結果,因此研究公司財務情況是有意義的。在本文中,我們決定重點研究雲南白藥集團的roe。

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.

對於股東來說,股東回報率(ROE)是一個重要的考慮因素,因爲它告訴股東他們的資本被有效地再投資了多少。換句話說,它是一個衡量公司股東提供的資本回報率的盈利能力比率。

How Do You Calculate Return On Equity?

怎樣計算ROE?

The formula for return on equity is:

權益回報率的計算公式是:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

淨資產收益率 = 淨利潤(從持續經營中獲得)÷ 股東權益

So, based on the above formula, the ROE for Yunnan Baiyao GroupLtd is:

因此,根據上述公式,雲南白藥集團的roe爲:

10% = CN¥4.3b ÷ CN¥42b (Based on the trailing twelve months to March 2024).

10%= CN¥43億 ÷ CN¥420億 (基於截至2024年3月的過去十二個月)。

The 'return' is the yearly profit. One way to conceptualize this is that for each CN¥1 of shareholders' capital it has, the company made CN¥0.10 in profit.

“回報”是年利潤。可以這樣理解,對於每1元股東資本,公司獲得了0.10元的利潤。

Why Is ROE Important For Earnings Growth?

ROE對於盈利增長的重要性是什麼?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

到目前爲止,我們已經了解到ROE衡量公司如何高效地生成利潤。現在我們需要評估公司以後的增長潛力,即公司重新投資或“保留”的利潤。其他條件相同的情況下,同時具有較高的股權回報率和較高的利潤保留的公司通常是相對於不具備相同特點的公司而言增長率更高的公司。

A Side By Side comparison of Yunnan Baiyao GroupLtd's Earnings Growth And 10% ROE

雲南白藥集團的盈利增長和10%roe的並行對比

When you first look at it, Yunnan Baiyao GroupLtd's ROE doesn't look that attractive. Although a closer study shows that the company's ROE is higher than the industry average of 7.6% which we definitely can't overlook. However, Yunnan Baiyao GroupLtd's five year net income decline rate was 2.7%. Bear in mind, the company does have a slightly low ROE. It is just that the industry ROE is lower. So that could be one of the factors that are causing earnings growth to shrink.

乍一看,雲南白藥集團的roe並不那麼有吸引力。儘管更仔細的研究表明,該公司的roe高於行業平均水平7.6%,我們無疑不能忽略這一點。然而,雲南白藥集團的五年淨利潤下降率爲2.7%。請記住,公司的roe略低,只是行業roe更低。因此,這可能是導致收益增長下降的因素之一。

That being said, we compared Yunnan Baiyao GroupLtd's performance with the industry and were concerned when we found that while the company has shrunk its earnings, the industry has grown its earnings at a rate of 9.2% in the same 5-year period.

話雖如此,我們將雲南白藥集團的表現與行業進行了比較,結果發現,而公司收益縮水,而同一5年週期內行業的收益增長率卻爲9.2%。

big
SZSE:000538 Past Earnings Growth July 18th 2024
SZSE:000538過去的盈利增長2024年7月18日

Earnings growth is a huge factor in stock valuation. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Has the market priced in the future outlook for 000538? You can find out in our latest intrinsic value infographic research report.

盈利增長是股票估值的一個重要因素。投資者了解市場是否對公司的預期盈利增長(或下降)進行了定價非常重要。通過這樣做,他們會知道股票是進入明確的藍水區還是等待着泥濘的沼澤地。市場是否已經對000538的未來展望定價?請看我們最新的固有價值信息圖研究報告。

Is Yunnan Baiyao GroupLtd Efficiently Re-investing Its Profits?

雲南白藥集團高效地再投資利潤嗎?

Yunnan Baiyao GroupLtd's declining earnings is not surprising given how the company is spending most of its profits in paying dividends, judging by its three-year median payout ratio of 81% (or a retention ratio of 19%). With only a little being reinvested into the business, earnings growth would obviously be low or non-existent.

考慮到雲南白藥集團的三年中位數派息率爲81%(或保留率爲19%),該公司的盈利下降並不令人意外。只有一小部分被再投資到業務中,因此收益增長顯然會很低或不存在。此外,雲南白藥集團已經支付股息至少十年,這表明即使以業務增長爲代價,維持股息支付也更爲重要。我們最新的分析師數據顯示,未來三年公司的股息支付比率預計約爲82%。因此,分析師預測公司未來的roe也不會有太大變化,預測roe爲12%。

In addition, Yunnan Baiyao GroupLtd has been paying dividends over a period of at least ten years suggesting that keeping up dividend payments is way more important to the management even if it comes at the cost of business growth. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 82%. Therefore, the company's future ROE is also not expected to change by much with analysts predicting an ROE of 12%.

總的來說,我們對雲南白藥集團持有複雜的情感。首先,在ROE適度的情況下,我們很失望收益沒有增長。請記住,公司只再投資了一小部分利潤,這也解釋了增長的缺乏。但是,我們研究了最新的分析師預測,並發現儘管公司過去曾收縮過收益,在未來分析師預計其收益將增長。要了解有關公司未來盈利增長預測的更多信息,請查看有關該公司的分析師預測的免費報告。

Conclusion

結論

Overall, we have mixed feelings about Yunnan Baiyao GroupLtd. Primarily, we are disappointed to see a lack of growth in earnings even in spite of a moderate ROE. Bear in mind, the company reinvests a small portion of its profits, which explains the lack of growth. With that said, we studied the latest analyst forecasts and found that while the company has shrunk its earnings in the past, analysts expect its earnings to grow in the future. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論